Form 4: Director Wanda M. Austin Acquires Amgen Shares

Amgen Inc. Director Wanda M. Austin acquired 665 shares of common stock through the vesting of restricted stock units.

Summary

• Director Wanda M. Austin acquired 665 shares of Amgen Inc. common stock on May 19, 2026.
• The acquisition resulted from the immediate vesting of Restricted Stock Units (RSUs).
• The transaction was executed at a price of $0 per share as part of the Director Incentive Program.
• Following this transaction, the director's total beneficial ownership stands at 8,018 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Increased equity alignment between the director and shareholders.
• Standard compensation-related equity grant indicating continued board participation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a routine disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that this is a routine regulatory disclosure regarding director compensation within the biotechnology sector, reflecting standard corporate governance practices for equity-based incentive programs.

Comparison to Industry Standards

• The use of RSUs for director compensation is a standard practice among large-cap pharmaceutical and biotechnology companies like Amgen.
• The immediate vesting and one-to-one conversion ratio align with typical equity incentive plan structures for board members.

Stakeholder Impact

• Minimal impact on shareholders as this represents standard director compensation.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Amgen, AMGN, Insider Trading, Form 4, Director Compensation, Equity Incentive Plan